GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004427025 | Thyroid | ATC | cellular nitrogen compound catabolic process | 229/6293 | 451/18723 | 2.25e-14 | 1.27e-12 | 229 |
GO:000641735 | Thyroid | ATC | regulation of translation | 236/6293 | 468/18723 | 2.39e-14 | 1.34e-12 | 236 |
GO:001943924 | Thyroid | ATC | aromatic compound catabolic process | 232/6293 | 467/18723 | 3.05e-13 | 1.44e-11 | 232 |
GO:004572733 | Thyroid | ATC | positive regulation of translation | 85/6293 | 136/18723 | 4.71e-12 | 1.84e-10 | 85 |
GO:003425034 | Thyroid | ATC | positive regulation of cellular amide metabolic process | 97/6293 | 162/18723 | 5.97e-12 | 2.30e-10 | 97 |
GO:190136124 | Thyroid | ATC | organic cyclic compound catabolic process | 238/6293 | 495/18723 | 1.12e-11 | 4.12e-10 | 238 |
GO:190331324 | Thyroid | ATC | positive regulation of mRNA metabolic process | 75/6293 | 118/18723 | 2.57e-11 | 8.84e-10 | 75 |
GO:004348725 | Thyroid | ATC | regulation of RNA stability | 97/6293 | 170/18723 | 2.68e-10 | 7.70e-09 | 97 |
GO:006101325 | Thyroid | ATC | regulation of mRNA catabolic process | 95/6293 | 166/18723 | 3.27e-10 | 9.16e-09 | 95 |
GO:004348826 | Thyroid | ATC | regulation of mRNA stability | 90/6293 | 158/18723 | 1.31e-09 | 3.30e-08 | 90 |
GO:0061157110 | Thyroid | ATC | mRNA destabilization | 52/6293 | 84/18723 | 1.01e-07 | 1.70e-06 | 52 |
GO:0061014110 | Thyroid | ATC | positive regulation of mRNA catabolic process | 53/6293 | 87/18723 | 1.63e-07 | 2.61e-06 | 53 |
GO:0050779110 | Thyroid | ATC | RNA destabilization | 53/6293 | 88/18723 | 2.75e-07 | 4.20e-06 | 53 |
GO:009872722 | Thyroid | ATC | maintenance of cell number | 70/6293 | 134/18723 | 6.45e-06 | 6.69e-05 | 70 |
GO:001982722 | Thyroid | ATC | stem cell population maintenance | 67/6293 | 131/18723 | 2.48e-05 | 2.16e-04 | 67 |
GO:003090015 | Thyroid | ATC | forebrain development | 164/6293 | 379/18723 | 4.85e-05 | 3.87e-04 | 164 |
GO:003424923 | Thyroid | ATC | negative regulation of cellular amide metabolic process | 121/6293 | 273/18723 | 1.36e-04 | 9.57e-04 | 121 |
GO:001714823 | Thyroid | ATC | negative regulation of translation | 107/6293 | 245/18723 | 6.17e-04 | 3.51e-03 | 107 |
GO:004206323 | Thyroid | ATC | gliogenesis | 127/6293 | 301/18723 | 1.07e-03 | 5.66e-03 | 127 |
GO:004341412 | Thyroid | ATC | macromolecule methylation | 131/6293 | 316/18723 | 2.01e-03 | 9.60e-03 | 131 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
METTL14 | SNV | Missense_Mutation | | c.586N>A | p.Glu196Lys | p.E196K | Q9HCE5 | protein_coding | tolerated(0.14) | probably_damaging(0.966) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
METTL14 | insertion | Nonsense_Mutation | novel | c.1365_1366insTGGACCAACGCTTACAAATAGCAACTACAATGCAGAAA | p.Arg456TrpfsTer7 | p.R456Wfs*7 | Q9HCE5 | protein_coding | | | TCGA-A8-A0A4-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | CR |
METTL14 | insertion | In_Frame_Ins | novel | c.22_23insATATTAACAATAACAAGCACT | p.Ile8delinsAsnIleAsnAsnAsnLysHisPhe | p.I8delinsNINNNKHF | Q9HCE5 | protein_coding | | | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
METTL14 | deletion | Frame_Shift_Del | novel | c.688delN | p.Phe230LeufsTer46 | p.F230Lfs*46 | Q9HCE5 | protein_coding | | | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD |
METTL14 | SNV | Missense_Mutation | | c.893N>A | p.Arg298His | p.R298H | Q9HCE5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A959-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
METTL14 | SNV | Missense_Mutation | | c.19G>C | p.Glu7Gln | p.E7Q | Q9HCE5 | protein_coding | tolerated_low_confidence(0.22) | probably_damaging(0.932) | TCGA-XS-A8TJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
METTL14 | SNV | Missense_Mutation | | c.803N>C | p.Asn268Thr | p.N268T | Q9HCE5 | protein_coding | tolerated(0.16) | possibly_damaging(0.843) | TCGA-A6-6138-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
METTL14 | SNV | Missense_Mutation | novel | c.213N>C | p.Glu71Asp | p.E71D | Q9HCE5 | protein_coding | tolerated_low_confidence(0.34) | benign(0.039) | TCGA-AA-3862-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
METTL14 | SNV | Missense_Mutation | novel | c.1286N>T | p.Arg429Ile | p.R429I | Q9HCE5 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.962) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
METTL14 | SNV | Missense_Mutation | | c.10N>A | p.Arg4Ser | p.R4S | Q9HCE5 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.931) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |